Smart Sand, Inc. announced it will participate in a webcast presentation and hold one-on-one investor meetings at the virtual Lytham Partners Fall 2026 Investor Conference on September 29, 2026. The company, which supplies high-quality frac and industrial sand used in hydraulic fracturing and various industrial applications, will showcase its operations and growth prospects. This event provides Smart Sand an opportunity to engage directly with investors and highlight its integrated supply and logistics solutions. The webcast will be accessible live and available for replay after the event.
Smart Sand, Inc. is featured in this news with Pluang's Basic Materials sector data as context. For readers following Basic Materials, here is Pluang's market snapshot as of Sep 16, 2026 01:22 WIB: Of 32 priced US stocks, 16 rose and 16 fell. Notable movers include DuPont de Nemours Inc at USD 126.56 (+1.81%), Nucor Corporation at USD 259.04 (+1.73%), and Lithium Americas Corp at USD 2.84 (-1.73%).
Uber Technologies reported a 25% year-over-year increase in gross bookings to $53.7 billion in Q1 2026, driven by growth in ride-hailing, delivery, grocery, retail, and membership services. CEO Dara Khosrowshahi's recent purchase of 141,000 shares wo...
Waystar Holding Corp, a healthcare software company valued at around $5.1 billion, saw its stock rise 8.6% to $27.05 following reports that it is evaluating strategic options, including a potential sale. Barclays set a new price target of $30, sugges...
MasterCraft Boat Holdings reported fiscal Q4 2026 adjusted earnings of $0.67 per share and revenue of $129.94 million, surpassing estimates. Revenue growth was driven by its Performance and Wake business and the Marine Products acquisition, which add...
Redwood Trust's CFO, Carillo Brooke, increased her stake by purchasing 26,065 shares, showing confidence despite a major shareholder urging the board to consider selling the company. The stock trades at a 33% discount to its GAAP book value due to ri...
BioMarin Pharmaceutical received a price target upgrade to $97 from BMO Capital, reflecting about 50% upside from current levels. This follows positive Phase 3 trial results for VOXZOGO®, a treatment for hypochondroplasia, showing significant growth ...
